2013
DOI: 10.1002/mnfr.201200827
|View full text |Cite
|
Sign up to set email alerts
|

Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega‐3 fatty acids

Abstract: Scope In contrast to well-characterized polyunsaturated fatty acid (PUFA) levels in serum, little is known regarding their downstream metabolic products. However, many of these compounds are lipid mediators with prominent roles during pro- and anti-inflammatory processes. Methods and Results In this double blind crossover study on asthmatics, shifts in serum levels of ω-3 and ω-6 PUFA-derived oxidized fatty acids (e.g., eicosanoids, oxylipins) were quantified following dietary fish oil supplementation. Serum… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

8
30
1

Year Published

2014
2014
2023
2023

Publication Types

Select...
6
2
1

Relationship

2
7

Authors

Journals

citations
Cited by 46 publications
(39 citation statements)
references
References 57 publications
8
30
1
Order By: Relevance
“…These in vivo fi ndings are in line with the results of previous in vitro studies on recombinant enzymes showing that various human AA-metabolizing CYP isoforms accept EPA and DHA as effi cient alternative substrates ( 1,(19)(20)(21)(22). Our results also indicate that CYP-eicosanoid and vicinal diols were reported from studies that treated healthy volunteers for 4 weeks with 4 g of an EPA/DHA supplement ( 46 ) or asthmatic patients for three weeks with 4 g EPA + 2 g DHA per day ( 47 ). Even without dietary intervention, the individual differences in the serum concentrations of EPA-derived epoxy-and dihydroxy-metabolites correlated well with the EPA content in RBCs, as shown in a recent study comparing the metabolite profi les in hyperand normolipidemic men ( 48 ).…”
Section: Discussionsupporting
confidence: 91%
“…These in vivo fi ndings are in line with the results of previous in vitro studies on recombinant enzymes showing that various human AA-metabolizing CYP isoforms accept EPA and DHA as effi cient alternative substrates ( 1,(19)(20)(21)(22). Our results also indicate that CYP-eicosanoid and vicinal diols were reported from studies that treated healthy volunteers for 4 weeks with 4 g of an EPA/DHA supplement ( 46 ) or asthmatic patients for three weeks with 4 g EPA + 2 g DHA per day ( 47 ). Even without dietary intervention, the individual differences in the serum concentrations of EPA-derived epoxy-and dihydroxy-metabolites correlated well with the EPA content in RBCs, as shown in a recent study comparing the metabolite profi les in hyperand normolipidemic men ( 48 ).…”
Section: Discussionsupporting
confidence: 91%
“…Similar results have also been demonstrated in patients with chronic stable disease, including asthma and IgA nephropathy ( 14,31 ). Each of these prior studies was quite small (n = 10 to 30) and did not include evaluation of MEFA responses following acute tissue stress/ infl ammation, when their function may be most relevant.…”
Section: Discussionsupporting
confidence: 57%
“…Further, flax oil feeding slows disease progression in the pcy mouse [13], as well as other models of renal disease [14][15][16], and since dietary n-3 fatty acids can alter fatty acid and oxylipin compositions [17,18], we examined whether flax oil feeding would increase DHA levels and whether it would affect any of the renal oxylipin alterations in this disease.…”
Section: Introductionmentioning
confidence: 99%